NCT07341321Recruiting
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma). Secondary Objectives: Evaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 15 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Medical University of Graz
- NCT number
- NCT07341321
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2026 to the primary completion date, Jul 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Missing key clinical data required for main analyses (e.g. survival status, date of progression, Child-Pugh class, BCLC stage)
Who the study is looking for
- Age ≥ 18 years
- Radiologically or histologically confirmed hepatocellular carcinoma
- Treatment with immune checkpoint inhibitor-based therapy (mono- or combination therapy; e.g., atezolizumab/bevacizumab, durvalumab/tremelimumab, nivolumab, pembrolizumab)
- Complete electronic medical records available
- At least one imaging-based response assessment using mRECIST
Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Graz Coordinator of this site? Confirm its status | Graz | Austria | Recruiting |
| Ordensklinikum Linz Coordinator of this site? Confirm its status | Linz | Austria | Not yet recruiting |
| University Hospital St. Pölten Coordinator of this site? Confirm its status | Sankt Pölten | Austria | Not yet recruiting |
| Krankenhaus der Barmherzigen Brüder St Veit an der Glan Coordinator of this site? Confirm its status | Sankt Veit an der Glan | Austria | Recruiting |
| Klinikum Wels-Grieskirchen Coordinator of this site? Confirm its status | Wels | Austria | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.